GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (NAS:NTBL) » Definitions » Debt-to-Asset

Notable Labs (Notable Labs) Debt-to-Asset : 0.11 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Notable Labs Debt-to-Asset?

Notable Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.52 Mil. Notable Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.53 Mil. Notable Labs's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $19.54 Mil. Notable Labs's debt to asset for the quarter that ended in Dec. 2023 was 0.10.

Notable Labs Debt-to-Asset Historical Data

The historical data trend for Notable Labs's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Notable Labs Debt-to-Asset Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Asset
0.22 0.07 0.11

Notable Labs Semi-Annual Data
Dec21 Dec22 Dec23
Debt-to-Asset 0.22 0.07 0.11

Competitive Comparison of Notable Labs's Debt-to-Asset

For the Biotechnology subindustry, Notable Labs's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Notable Labs's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Notable Labs's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Notable Labs's Debt-to-Asset falls into.


Notable Labs Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Notable Labs's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.523 + 1.526) / 19.541
=0.10

Notable Labs's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.523 + 1.526) / 19.541
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Notable Labs  (NAS:NTBL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Notable Labs Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Notable Labs's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Notable Labs (Notable Labs) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (NAS:NTBL) » Definitions » Debt-to-Asset
Comparable Companies
NLSP ACST AGE CRBP NBIO CLRB AIM PLUR BIXT SNSE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
320 Hatch Drive, Foster City, CA, USA, 94404
Website
https://notablelabs.com
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic.